Fri, Aug 1, 2014, 9:19 PM EDT - U.S. Markets closed


% | $
Click the to save as a favorite.

Boston Scientific Corporation Message Board

favela808 2 posts  |  Last Activity: May 16, 2014 4:40 PM Member since: Jan 23, 2003
  • Abstract:

    Background: More effective treatment is needed for chemotherapy-induced peripheral neuropathy (CIPN). Preliminary data support the use of Scrambler therapy, a device which treats pain via non-invasive cutaneous electrostimulation, for the treatment of CIPN (Smith TJ et al. J Pain Symptom Manage 2010). The current abstract reports data from a pilot trial, performed to investigate the effect of Scrambler therapy for the treatment of established CIPN. Methods: Eligible patients: age ≥ 18 years, ECOG PS ≤2, life expectancy ≥3 months, CIPN symptoms of ≥1 month duration with tingling and/or pain ≥4/10 during the prior week. Patients were treated with Scrambler therapy to the affected area(s) for up to 10 daily 30 minute sessions. Symptoms were monitored using a neuropathy questionnaire consisting of numerical analogue scales ranging from 0-10, daily before therapy as well as weekly for 10 weeks after therapy. Descriptive summary statistics formed the basis of data analysis. During the daily therapy, last values carried forward were used. Results: We report on 37 patients enrolled between 7/18/2011 and 5/6/2013, 12 men and 25 women; the mean age was 58. While the study technically remains open to obtain more experience with this procedure, the first 37 accrued CIPN patients are the basis of our final CIPN-related manuscript from this project (in development). Patients had a history of exposure to various neurotoxic chemotherapeutic agents and the majority (78%) had symptoms ≥1 year. 25 patients were treated primarily on their lower extremities while 12 were treated primarily on their upper extremities. The table portrays data (average symptoms during the previous 24 hours) at baseline, on the last of the 10 planned days of therapy, and at the end of 10 weeks of follow up, regarding patient reported pain, tingling, and numbness. There were no substantial adverse events. Conclusions: Scrambler therapy appears to be effective for the treatment of CIPN:

    Sentiment: Strong Buy

  • Competitive Tech to Host Private Engagement for Top Opinion Leaders at the ASCO 2014 Annual Meeting
    Guest Speakers to Discuss Calmare® Pain Device Therapy Treatment; Company Developed Medical Milestones and Advancements to be Disclosed
    Conference: May 30 - June 3, 2014 | The McCormick Center, Chicago, IL | Booth 5072
    Private Engagement: June 1, 2014 | Hyatt Regency McCormick Place, Chicago, IL
    PR Newswire Competitive Technologies, Inc.
    21 hours ago
    FAIRFIELD, Conn., May 6, 2014 /PRNewswire/ -- Competitive Technologies, Inc., (CTI), the pain mitigation company, will host a private engagement for top opinion leaders in oncology at the Hyatt Regency McCormick Place on June 1, 2014 during the 50th Annual American Society of Clinical Oncology (ASCO) in Chicago, IL.

    At the private engagement, there will be a morning panel discussion on the treatment of chemotherapy-induced peripheral neuropathy (CIPN) using Calmare Pain Device Therapy. The panel will consist of Dr. Thomas J. Smith from the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Medicine and Dr. Charles L. Loprinzi, Regis Professor of Breast Cancer Research, Division of Medical Oncology at the Mayo Clinic.

    CTI will exhibit and feature their signature device, the Calmare Pain Device, at Booth 5072 at the McCormick Center during ASCO.

    "ASCO 50th annual meeting is the perfect venue to introduce Calmare to the world's top opinion leaders," commented CTI President & CEO Conrad Mir. "We feel Calmare therapy may be the alternative therapy that alternative therapy that patients, plagued with chronic pain, need in order to return to a pain-free lifestyle. As a medical device Company furthering such an innovative product, it is important that the medical community is made aware of this non-invasive approach that may revolutionize the way pain is managed."

    Sentiment: Strong Buy

12.59-0.19(-1.49%)Aug 1 4:01 PMEDT

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.